Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $817.63 million. The enterprise value is $461.41 million.
| Market Cap | 817.63M |
| Enterprise Value | 461.41M |
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 51.55 million shares outstanding. The number of shares has increased by 5.48% in one year.
| Current Share Class | 51.55M |
| Shares Outstanding | 51.55M |
| Shares Change (YoY) | +5.48% |
| Shares Change (QoQ) | -3.34% |
| Owned by Insiders (%) | 6.37% |
| Owned by Institutions (%) | 49.75% |
| Float | 23.70M |
Valuation Ratios
The trailing PE ratio is 7.17 and the forward PE ratio is 7.09.
| PE Ratio | 7.17 |
| Forward PE | 7.09 |
| PS Ratio | 7.43 |
| Forward PS | 8.12 |
| PB Ratio | 2.76 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | 3.03 |
| P/OCF Ratio | 3.03 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 70.17, with an EV/FCF ratio of 1.72.
| EV / Earnings | 4.03 |
| EV / Sales | 4.20 |
| EV / EBITDA | 70.17 |
| EV / EBIT | 92.61 |
| EV / FCF | 1.72 |
Financial Position
The company has a current ratio of 13.14, with a Debt / Equity ratio of 0.14.
| Current Ratio | 13.14 |
| Quick Ratio | 12.91 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 6.16 |
| Debt / FCF | 0.15 |
| Interest Coverage | 2.74 |
Financial Efficiency
Return on equity (ROE) is 50.17% and return on invested capital (ROIC) is -3.66%.
| Return on Equity (ROE) | 50.17% |
| Return on Assets (ROA) | 0.76% |
| Return on Invested Capital (ROIC) | -3.66% |
| Return on Capital Employed (ROCE) | 1.13% |
| Weighted Average Cost of Capital (WACC) | 5.22% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | $1.27M |
| Employee Count | 90 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $22.37 million in taxes.
| Income Tax | 22.37M |
| Effective Tax Rate | 16.34% |
Stock Price Statistics
The stock price has increased by +40.90% in the last 52 weeks. The beta is 0.19, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +40.90% |
| 50-Day Moving Average | 16.34 |
| 200-Day Moving Average | 16.49 |
| Relative Strength Index (RSI) | 36.38 |
| Average Volume (20 Days) | 375,163 |
Short Selling Information
The latest short interest is 4.99 million, so 9.69% of the outstanding shares have been sold short.
| Short Interest | 4.99M |
| Short Previous Month | 5.16M |
| Short % of Shares Out | 9.69% |
| Short % of Float | 21.07% |
| Short Ratio (days to cover) | 14.12 |
Income Statement
In the last 12 months, TBPH had revenue of $109.78 million and earned $114.54 million in profits. Earnings per share was $2.21.
| Revenue | 109.78M |
| Gross Profit | 77.98M |
| Operating Income | 4.98M |
| Pretax Income | 136.92M |
| Net Income | 114.54M |
| EBITDA | 6.58M |
| EBIT | 4.98M |
| Earnings Per Share (EPS) | $2.21 |
Balance Sheet
The company has $394.67 million in cash and $40.50 million in debt, with a net cash position of $354.16 million or $6.87 per share.
| Cash & Cash Equivalents | 394.67M |
| Total Debt | 40.50M |
| Net Cash | 354.16M |
| Net Cash Per Share | $6.87 |
| Equity (Book Value) | 290.59M |
| Book Value Per Share | 5.64 |
| Working Capital | 385.86M |
Cash Flow
In the last 12 months, operating cash flow was $268.78 million and capital expenditures -$42,000, giving a free cash flow of $268.74 million.
| Operating Cash Flow | 268.78M |
| Capital Expenditures | -42,000 |
| Depreciation & Amortization | 1.59M |
| Net Borrowing | n/a |
| Free Cash Flow | 268.74M |
| FCF Per Share | $5.21 |
Margins
Gross margin is 71.04%, with operating and profit margins of 4.54% and 104.34%.
| Gross Margin | 71.04% |
| Operating Margin | 4.54% |
| Pretax Margin | 124.72% |
| Profit Margin | 104.34% |
| EBITDA Margin | 5.99% |
| EBIT Margin | 4.54% |
| FCF Margin | 244.81% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.48% |
| Shareholder Yield | -5.48% |
| Earnings Yield | 14.04% |
| FCF Yield | 32.95% |
Analyst Forecast
The average price target for TBPH is $17.40, which is 9.71% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.40 |
| Price Target Difference | 9.71% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of 1.04 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.04 |
| Piotroski F-Score | 7 |